Panacea Biotec Consolidated September 2022 Net Sales at Rs 105.12 crore, down 54.72% Y-o-Y
NULL15-11-2022
PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated November 14, 2022 for approving the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company for the Quarter and Half Year ended September 30, 2022 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of the Extract of Statement of aforesaid Unaudited Financial Results published in the attached newspapers on November 15, 202215-11-2022
PANACEA BIOTEC LTD. - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2022
We would like to inform you that Board of Directors of the Company has, at its meeting held today, i.e. 14.11.2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended 30.09.2022. The same were also reviewed by the Audit Committee in its meeting held earlier on 14.11.2022. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. We wish to further inform you that the Board of Directors has also decided the elevation of Dr. Rajesh Jain, Managing Director to the position of Chairman & Managing Director of the Company. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 4:40 P.M. We request you to kindly bring the above information to the notice of your members.14-11-2022
PANACEA BIOTEC LTD. - 531349 - Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2022
We would like to inform you that Board of Directors of the Company has, at its meeting held today, i.e. 14.11.2022, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended 30.09.2022. The same were also reviewed by the Audit Committee in its meeting held earlier on 14.11.2022. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure - A. We wish to further inform you that the Board of Directors has also decided the elevation of Dr. Rajesh Jain, Managing Director to the position of Chairman & Managing Director of the Company. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 4:40 P.M. We request you to kindly bring the above information to the notice of your members.14-11-2022
PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to CDSL''s Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed, we are enclosing herewith the data of shares dematerialized during the month of September, 2022 as Annexure - 1. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd., regarding shares dematerialized as on September 30. 2022 is also enclosed as Annexure -2.07-11-2022
PANACEA BIOTEC LTD. - 531349 - Board Meeting Intimation for Board Meeting On November 14, 2022 For Approving The Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Half Year Ended September 30, 2022
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI LODR Regulations, this is to inform you that: (i) a meeting of the Board of Directors of the Company is scheduled to be held on Monday, 14.11.2022 at New Delhi, inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended 30.09.2022. (ii) pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company. (iii) with reference to our earlier announcement dated 29.09.2022 intimating the Closure of Trading Window pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons till 16.11.2022 and the same will re-open from 17.11.2022. This is for your kind information and record please.04-11-2022
PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Serum Institute of India Pvt Ltd12-10-2022
PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
The Company has received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT(r) (DTwP-HepB-Hib). UNICEF award is worth US$ 98.755 million (~INR 813 Crore) for supply of ~99.70 million doses during calendar years 2023-2027 and PAHO award is worth US$ 28.55 million (~INR 235 Crore) for supply ~24.83 million doses during calendar years 2023-2025. A copy of the Press Release titled 'Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine (DTwP-HepB-Hib)' being issued to the media, etc. in this regard is enclosed for your kind reference and record please10-10-2022
PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith a certificate dated October 06, 2022, issued by Skyline Financial Services Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2022.07-10-2022
PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Details of Shares dematerialized during September, 2022 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 is enclosed herewith.07-10-2022